Unknown

Dataset Information

0

Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.

ABSTRACT:

SUBMITTER: Nichols TC 

PROVIDER: S-EPMC3360416 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.

Nichols T C TC   Franck H W G HW   Franck C T CT   De Friess N N   Raymer R A RA   Merricks E P EP  

Journal of thrombosis and haemostasis : JTH 20120301 3

Similar Datasets

Unknown Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice.
| S-EPMC10481914 | biostudies-literature
Unknown A Highly Productive CHO Cell Line Secreting Human Blood Clotting Factor IX.
| S-EPMC5916734 | biostudies-literature
Unknown Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis.
| S-EPMC10491823 | biostudies-literature
Unknown Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
| S-EPMC6029626 | biostudies-literature
Unknown Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model.
| S-EPMC3947717 | biostudies-literature
Unknown Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab.
| S-EPMC11419781 | biostudies-literature
Unknown Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
| S-EPMC4278802 | biostudies-literature
Unknown Discovery of An Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B.
| S-EPMC6981973 | biostudies-literature
Unknown Mathematical modeling identifies clotting factor combinations that modify thrombin generation in normal and factor VIII-, IX-, or XI-deficient blood.
| S-EPMC11491717 | biostudies-literature
Unknown Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX.
| S-EPMC5987250 | biostudies-literature